Xie, Cong http://orcid.org/0000-0002-0054-9269
Iroga, Peter
Bound, Michelle J.
Grivell, Jacqueline
Huang, Weikun http://orcid.org/0000-0001-9400-3840
Jones, Karen L. http://orcid.org/0000-0002-1155-5816
Horowitz, Michael http://orcid.org/0000-0002-0942-0306
Rayner, Christopher K. http://orcid.org/0000-0002-5527-256X
Wu, Tongzhi http://orcid.org/0000-0003-1656-9210
Funding for this research was provided by:
Royal Adelaide Hospital Research Fund (Mary Overton Early Career Fellowship)
University of Adelaide (William T Southcott Senior Research Fellowship)
Hospital Research Foundation (Mid-Career Fellowship)
The University of Adelaide
Article History
Received: 15 January 2024
Accepted: 14 February 2024
First Online: 1 April 2024
Acknowledgements
: The authors wish to thank Kylie Lange (Centre of Research Excellence in Translating Nutritional Science into Good Health, The University of Adelaide, Australia) for her expert statistical advice, and Scott Standfield and Judith Wishart (Centre of Research Excellence in Translating Nutritional Science into Good Health, The University of Adelaide, Australia) for performing the GLP-1 and insulin assays. The data were presented as an oral presentation at the 59th EASD Annual Meeting in 2023.
: The datasets generated during and/or analysed during the current study are not publicly available but are available from the corresponding author on reasonable request.
: CX is supported by the Royal Adelaide Hospital Mary Overton Early Career Fellowship. KLJ is supported by the William T. Southcott Senior Research Fellowship from the University of Adelaide. TW is supported by a Mid-Career Fellowship from The Hospital Research Foundation, South Australia.
: KLJ has received research funding from Sanofi, Aventis and AstraZeneca, and is a shareholder for Glyscend. MH has participated in advisory boards and/or symposia for Novo Nordisk, Sanofi, Novartis, Eli Lilly, Merck Sharp & Dohme, Boehringer Ingelheim, Inova and AstraZeneca, and has received honoraria for this activity, and is a shareholder for both Satiogen and Glyscend. CKR has received research funding from AstraZeneca, Merck Sharp & Dohme, Eli Lilly, Novartis and Sanofi, and is a shareholder for both Satiogen and Glyscend. TW has received travel support from Novartis and Sanofi and research funding from Novartis and AstraZeneca. The remaining authors declare that there are no relationships or activities that might bias, or be perceived to bias, their work.
: CX was involved in the conception and design of the study, data collection and interpretation, statistical analysis and writing the manuscript. PI, MJB, JG and WH were involved in data collection and interpretation, and review of the manuscript. KLJ, MH and CKR were involved in the conception and design of the study, data interpretation and review of the manuscript. TW was involved in the conception and design of the study, data interpretation, statistical analysis and drafting of the manuscript, and is the guarantor of this work. All authors approved the final version of the manuscript.